RESUMO
Bifidobacterium longum subsp. infantis is a representative and dominant species in the infant gut and is considered a beneficial microbe. This organism displays multiple adaptations to thrive in the infant gut, regarded as a model for human milk oligosaccharides (HMOs) utilization. These carbohydrates are abundant in breast milk and include different molecules based on lactose. They contain fucose, sialic acid, and N-acetylglucosamine. Bifidobacterium metabolism is complex, and a systems view of relevant metabolic pathways and exchange metabolites during HMO consumption is missing. To address this limitation, a refined genome-scale network reconstruction of this bacterium is presented using a previous reconstruction of B. infantis ATCC 15967 as a template. The latter was expanded based on an extensive revision of genome annotations, current literature, and transcriptomic data integration. The metabolic reconstruction (iLR578) accounted for 578 genes, 1,047 reactions, and 924 metabolites. Starting from this reconstruction, we built context-specific genome-scale metabolic models using RNA-seq data from cultures growing in lactose and three HMOs. The models revealed notable differences in HMO metabolism depending on the functional characteristics of the substrates. Particularly, fucosyl-lactose showed a divergent metabolism due to a fucose moiety. High yields of lactate and acetate were predicted under growth rate maximization in all conditions, whereas formate, ethanol, and 1,2-propanediol were substantially lower. Similar results were also obtained under near-optimal growth on each substrate when varying the empirically observed acetate-to-lactate production ratio. Model predictions displayed reasonable agreement between central carbon metabolism fluxes and expression data across all conditions. Flux coupling analysis revealed additional connections between succinate exchange and arginine and sulfate metabolism and a strong coupling between central carbon reactions and adenine metabolism. More importantly, specific networks of coupled reactions under each carbon source were derived and analyzed. Overall, the presented network reconstruction constitutes a valuable platform for probing the metabolism of this prominent infant gut bifidobacteria.IMPORTANCEThis work presents a detailed reconstruction of the metabolism of Bifidobacterium longum subsp. infantis, a prominent member of the infant gut microbiome, providing a systems view of its metabolism of human milk oligosaccharides.
Assuntos
Fucose , Leite Humano , Lactente , Feminino , Humanos , Leite Humano/química , Fucose/análise , Lactose/análise , Oligossacarídeos/análise , Bifidobacterium/genética , Bifidobacterium longum subspecies infantis/metabolismo , Acetatos/análise , Carbono/análise , Lactatos/análiseRESUMO
Bifidobacterium longum is considered a microorganism with probiotic potential, which has been extensively studied, but these probiotic effects are strain dependent. This work aims to characterize the probiotic potential, based on the biochemical and genomic functionality, of B. longum LBUX23, isolated from neonates' feces. B. longum LBUX23 contains one circular genome of 2,287,838 bp with a G+C content of 60.05%, no plasmids, no CRISPR-Cas operon, possesses 56 tRNAs, 9 rRNAs, 1 tmRNA and 1776 coding sequences (CDSs). It has chromosomally encoded resistance genes to ampicillin and dicloxacillin, non-hemolytic activity, and moderate inhibition of Escherichia coli ATCC 25922 and to some emergent pathogen's clinical strains. B. longum LBUX23 was able to utilize lactose, sucrose, fructooligosaccharides (FOS), and lactulose. The maximum peak of bacterial growth was observed in sucrose and FOS at 6 h; in lactose and lactulose, it was shown at 8 h. B. longum LBUX23 can survive in gastrointestinal conditions (pH 4 to 7). A decrease in survival (96.5 and 93.8%) was observed at pH 3 and 3.5 during 120 min. argC, argH, and dapA genes could be involved in this tolerance. B. longum LBUX23 can also survive under primary and secondary glyco- or tauro-conjugated bile salts, and a mixture of bile salts due to the high extracellular bile salt hydrolase (BSH) activity (67.3 %), in taurocholic acid followed by taurodeoxycholic acid (48.5%), glycocholic acid (47.1%), oxgall (44.3%), and glycodeoxycholic acid (29.7%) probably due to the presence of the cbh and gnlE genes which form an operon (start: 119573 and end: 123812). Low BSH activity was determined intracellularly (<7%), particularly in glycocholic acid; no intracellular activity was shown. B. longum LBUX23 showed antioxidant effects in DPPH radical, mainly in intact cells (27.4%). In the case of hydroxyl radical scavenging capacity, cell debris showed the highest reduction (72.5%). In the cell-free extract, superoxide anion radical scavenging capacity was higher (90.5%). The genome of B. longum LBUX23 contains PNPOx, AhpC, Bcp, trxA, and trxB genes, which could be involved in this activity. Regarding adherence, it showed adherence up to 5% to Caco-2 cells. B. longum LBUX23 showed in vitro potential probiotic properties, mainly in BSH activity and antioxidant capacity, which indicates that it could be a good candidate for antioxidant or anti-cholesterol tests using in vivo models.
RESUMO
Food allergy is a pathological condition that can lead to hives, swelling, gastrointestinal distress, cardiovascular and respiratory compromise, and even anaphylaxis. The lack of treatment resources emphasizes the necessity for new therapeutic strategies, and in this way, probiotics has been pointed out as an alternative, especially because of its immunomodulatory properties. The goal of this study was to evaluate the probiotic effect of Bifidobacterium longum subsp. longum 51A (BL51A) in a murine model of ovalbumin (OVA) food allergy, as well as to investigate the effect of the dose and viability of the bacteria on the proposed model. For this purpose, the probiotic effect was assessed by clinical, immunological, and histological parameters in mice treated or not with the BL51A and sensitized or not with OVA. Oral administration of BL51A prevented weight loss and reduced serum levels of IgE anti-OVA and of sIgA in the intestinal fluid. Also, it reduced the intestinal permeability, proximal jejunum damage, recruitment of eosinophils and neutrophils, and levels of eotaxin-1, CXCL1/KC, IL4, IL5, IL6, IL13, and TNF. Furthermore, the treatment was able to increase the levels of IL10. Investigating different doses administered, the level of 108 CFU showed the best results in terms of protective effect. In addition, the administration of the inactivated bacteria did not present any beneficial effect. Results demonstrate that BL51A promotes a systemic immunomodulatory protective effect in a murine model of food allergy that depends on the dose and viability of the bacteria, suggesting its use as probiotic in such disease.
Assuntos
Hipersensibilidade Alimentar , Probióticos , Animais , Camundongos , Modelos Animais de Doenças , Hipersensibilidade Alimentar/tratamento farmacológico , Hipersensibilidade Alimentar/prevenção & controle , Bifidobacterium , Inflamação/tratamento farmacológicoRESUMO
Intestinal mucositis (IM) is a critical side-effect associated with antineoplastic therapy. Treatment available is only palliative and often not effective. However, alternative therapeutic strategies, such as probiotics, have attracted significant attention due to their immune-modulatory action in several diseases. Thus, the present study aims to elucidate the therapeutic potential of the probiotic strain Bifidobacterium longum 51A in a murine model of mucositis induced by irinotecan. Due to the scarcity of studies on dose-response and viability (probiotic vs paraprobiotic), we first evaluated which dose and cell viability would be most effective in treating mucositis. In this study, the oral pretreatment with viable B. longum 51A at a concentration of 1 × 109 CFU/mL reduced the daily disease activity index (p < 0.01), protected the intestinal architecture, preserved the length of the intestine (p < 0.05), and reduced intestinal permeability (p < 0.01), inflammation, and oxidative damage (p < 0.01) induced by irinotecan. Also, treatment with B. longum 51A increased the production of secretory immunoglobulin A (p < 0.05) in the intestinal fluid of mice with mucositis. Furthermore, B. longum 51A reversed the mucositis-induced increase in Enterobacteriaceae bacterial group in the gut (p < 0.01). In conclusion, these results showed that oral administration of B. longum 51A protects mice against intestinal damage caused by irinotecan, suggesting its use as a potential probiotic in therapy during mucositis.
Assuntos
Bifidobacterium longum , Microbioma Gastrointestinal/efeitos dos fármacos , Enteropatias , Irinotecano/efeitos adversos , Mucosite , Probióticos/farmacologia , Animais , Feminino , Enteropatias/induzido quimicamente , Enteropatias/microbiologia , Enteropatias/terapia , Irinotecano/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Mucosite/induzido quimicamente , Mucosite/microbiologia , Mucosite/terapiaRESUMO
Imbalances in gut microbiota composition occur in individuals with autism spectrum disorder (ASD). The administration of probiotics, prebiotics, and synbiotics is emerging as a potential and promising strategy for regulating the gut microbiota and improving ASD-related symptoms. We first investigated the survival of the probiotics Limosilactobacillus (L.) reuteri and Bifidobacterium (B.) longum alone, mixed and combined with a galacto-oligosaccharide (GOS) under simulated gastrointestinal conditions. Next, we evaluated the impact of probiotics (L. reuteri + B. longum), prebiotic (GOS), and synbiotic (L. reuteri + B. longum + GOS) on gut microbiota composition and metabolism of children with ASD using an in vitro fermentation model (SHIME®). The combination of L. reuteri, B. longum, and GOS showed elevated gastrointestinal resistance. The probiotic, prebiotic, and synbiotic treatments resulted in a positive modulation of the gut microbiota and metabolic activity of children with ASD. More specifically, the probiotic treatment increased the relative abundance of Lactobacillus, while the prebiotic treatment increased the relative abundance of Bifidobacterium and decreased the relative abundance of Lachnoclostridium. Changes in microbial metabolism were associated with increased short-chain fatty acid concentrations and reduced ammonium levels, particularly in the prebiotic and synbiotic treatments.
Assuntos
Transtorno do Espectro Autista , Transtorno Autístico , Microbioma Gastrointestinal , Probióticos , Simbióticos , Criança , Humanos , PrebióticosRESUMO
Bifidobacterium longum subsp. longum is a prevalent group in the human gut microbiome. Its persistence in the intestinal microbial community suggests a close host-microbe relationship according to age. The subspecies adaptations are related to metabolic capabilities and genomic and functional diversity. In this study, 154 genomes from public databases and four new Chilean isolates were genomically compared through an in silico approach to identify genomic divergence in genes associated with carbohydrate consumption and their possible adaptations to different human intestinal niches. The pangenome of the subspecies was open, which correlates with its remarkable ability to colonize several niches. The new genomes homogenously clustered within subspecies longum, as observed in phylogenetic analysis. B. longum SC664 was different at the sequence level but not in its functions. COG analysis revealed that carbohydrate use is variable among longum subspecies. Glycosyl hydrolases participating in human milk oligosaccharide use were found in certain infant and adult genomes. Predictive genomic analysis revealed that B. longum M12 contained an HMO cluster associated with the use of fucosylated HMOs but only endowed with a GH95, being able to grow in 2-fucosyllactose as the sole carbon source. This study identifies novel genomes with distinct adaptations to HMOs and highlights the plasticity of B. longum subsp. longum to colonize the human gut microbiota.
RESUMO
Allergic contact dermatitis (ACD) is a common allergic skin disease that affects individuals subjected to different antigen exposure conditions and significantly impacts the quality of life of those affected. Numerous studies have demonstrated that probiotics suppress inflammation through immunomodulatory effects. In this study, we aimed to evaluate the effect of the probiotic Bifidobacterium longum 51A as a preventive treatment for ACD using an oxazolone-induced murine model. We demonstrated that B. longum 51A exerted a prophylactic effect on oxazolone-induced ACD-like skin inflammation via reductions in ear and dermal thickness and leucocyte infiltration. The administration of inactivated B. longum 51A did not affect oxazolone-induced ACD-like skin inflammation, suggesting that the bacteria must be alive to be effective. Given that B. longum 51A is an acetate producer, we treated mice with acetate intraperitoneally, which also prevented ear and dermal thickening. Moreover, the tissue levels of the inflammatory cytokines and chemokines interleukin (IL)-10, IL-33, tumour necrosis factor-α, chemokine (C-C motif) ligand 2/monocyte chemoattractant protein-1 and chemokine (C-C motif) ligand 5/RANTES were significantly reduced after probiotic treatment, but only IL-33 and IL-10 were reduced when the mice were treated with acetate. These results show that B. longum 51A exerted a potential prophylactic effect on skin inflammation and that acetate represents one potential mechanism. However, other factors are likely involved since these two treatments do not yield the same results.
Assuntos
Bifidobacterium longum/fisiologia , Dermatite Alérgica de Contato/imunologia , Dermatite Alérgica de Contato/prevenção & controle , Probióticos/administração & dosagem , Animais , Citocinas/genética , Citocinas/imunologia , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/genética , Feminino , Humanos , Interleucina-10/genética , Interleucina-10/imunologia , Interleucina-33/genética , Interleucina-33/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Oxazolona/efeitos adversos , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/imunologiaRESUMO
This study evaluated the effects of Bifidobacterium longum 51A on the intestinal mucosa and inflammatory response in experimental colitis. Colitis was induced by administration of 3.5% dextran sodium sulphate (DSS) solution for 7 days. Two periods of administration were performed: treatment (T) group, mice received Bifidobacterium only during disease induction (7 days); total treatment (TT) group, mice received Bifidobacterium for 10 days before and during disease induction. The probiotic effects on intestinal permeability, inflammatory infiltrate, histological analysis, cytokines, chemokines and sIgA were evaluated. Bifidobacterium administration in the T group showed reduction in intestinal permeability and lower IL-1ß, myeloperoxidase, and eosinophil peroxidase levels compared to those in the colitis group (P<0.05). Bifidobacterium administration in the TT group attenuated severe lesions in the colon and reduced eosinophil peroxidase level (P<0.05). B. longum 51A treatment modality was more effective than total treatment and reduced the inflammatory response and its consequences on intestinal epithelium.
Assuntos
Bifidobacterium longum , Doenças Inflamatórias Intestinais/tratamento farmacológico , Probióticos/uso terapêutico , Animais , Colite/induzido quimicamente , Colo/efeitos dos fármacos , Colo/microbiologia , Colo/patologia , Citocinas/metabolismo , Modelos Animais de Doenças , Peroxidase de Eosinófilo/metabolismo , Feminino , Imunoglobulina A Secretora/metabolismo , Inflamação/tratamento farmacológico , Doenças Inflamatórias Intestinais/imunologia , Doenças Inflamatórias Intestinais/microbiologia , Interleucina-1beta/metabolismo , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Intestinos/efeitos dos fármacos , Intestinos/patologia , Camundongos , Camundongos Endogâmicos BALB C , Peroxidase/metabolismoRESUMO
Generation of uremic toxins p-cresylsulfate (p-CS), indoxyl sulfate (IS) and indole 3-acetic acid (IAA) in hemodialysis (HD) individuals may be associated with the gut flora and recognized markers of disease progression. This study investigated the effect of synbiotic meal on uremic toxins in HD individuals. We conducted randomized singleblind and placebo-controlled intervention study with 58 HD subjects (20F/38M, 63.1⯱â¯10.9-old) who were randomly allocated in synbiotic group (SG, 40â¯g of extruded sorghum plus 100â¯mL of unfermented probiotic milk) or control group (CG, 40â¯g of extruded corn plus 100â¯mL of pasteurized milk), during 7-wk Metabolic markers and uremic toxins, fecal concentration of short chain fatty acid and pH value was determined. The SG group had decreased serum p-CS and IS, as well as decreased urea concentration (pâ¯<â¯.05) compared to CG. SG showed higher fecal butyric acid and lower pH compared to baseline and SC (pâ¯<â¯.05). In addition, serum p-CS and fecal pH were positively correlated to urea concentration in SG participants at the endpoint. The consumption of the synbiotic meal during 7-wk reduced colonic pH, and reduced serum uremic (p-CS and IS) toxins and urea in HD subjects.
Assuntos
Refeições , Diálise Renal , Simbióticos , Ureia/toxicidade , Uremia/sangue , Idoso , Bifidobacterium longum , Biomarcadores/sangue , Brasil , Cresóis , Feminino , Microbioma Gastrointestinal , Humanos , Concentração de Íons de Hidrogênio , Indicã , Ácidos Indolacéticos , Masculino , Pessoa de Meia-Idade , Probióticos/uso terapêutico , Insuficiência Renal Crônica , Ésteres do Ácido Sulfúrico , Ureia/sangueRESUMO
Bifidobacteria represent one of the first colonizers of human gut microbiota, providing to this ecosystem better health and nutrition. To maintain a mutualistic relationship, they have enzymes to degrade and use complex carbohydrates non-digestible by their hosts. To succeed in the densely populated gut environment, they evolved molecular strategies that remain poorly understood. Herein, we report a novel mechanism found in probiotic Bifidobacteria for the depolymerization of the ubiquitous 2-acetamido-2-deoxy-4-O-(ß-d-mannopyranosyl)-d-glucopyranose (Man-ß-1,4-GlcNAc), a disaccharide that composes the universal core of eukaryotic N-glycans. In contrast to Bacteroidetes, these Bifidobacteria have a specialist and strain-specific ß-mannosidase that contains three distinctive structural elements conferring high selectivity for Man-ß-1,4-GlcNAc: a lid that undergoes conformational changes upon substrate binding, a tryptophan residue swapped between the two dimeric subunits to accommodate the GlcNAc moiety, and a Rossmann fold subdomain strategically located near to the active site pocket. These key structural elements for Man-ß-1,4-GlcNAc specificity are highly conserved in Bifidobacterium species adapted to the gut of a wide range of social animals, including bee, pig, rabbit, and human. Together, our findings uncover an unprecedented molecular strategy employed by Bifidobacteria to selectively uptake carbohydrates from N-glycans in social hosts.
Assuntos
Bifidobacterium/metabolismo , Microbioma Gastrointestinal/fisiologia , Trato Gastrointestinal/microbiologia , Polissacarídeos/metabolismo , beta-Manosidase/metabolismo , Animais , Domínio Catalítico , Ecossistema , Humanos , Triptofano/metabolismoRESUMO
BACKGROUND: Bifidobacterium genus are considered to be beneficial bacteria for their hosts; however, knowledge about the specific species that are part of the gut microbiome of howler monkeys is scarce. Polymerase chain reaction (PCR) is a useful technique for the identification of non-cultivable or difficult to grow bacterial species. With the goal of detecting species of the genus Bifidobacterium in black howler monkeys, we used PCR on DNA derived from faecal samples. METHODS: We collected and extracted DNA from 40 faecal samples. Using specific primers, we performed PCR and nested PCR to detect members of the Bifidobacterium genus and a subset of species: Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium animalis subsp. animalis. RESULTS: 97.5% (39/40) of the samples were positive for Bifidobacterium spp. We found B longum in 100% of the analysed samples. CONCLUSIONS: This is the first report of B longum in black howler monkey faeces.
Assuntos
Alouatta/microbiologia , Bifidobacterium/isolamento & purificação , Animais , Fezes/microbiologia , Feminino , Masculino , México , Reação em Cadeia da Polimerase/veterináriaRESUMO
This study aimed to evaluate the effects of three treatments, i.e., Bifidobacterium longum BB-46 (T1), B. longum BB-46 combined with the pectin (T2), and harsh extracted pectin from lemon (T3) on obesity-related microbiota using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®). The effects of the treatments were assessed by the analysis of the intestinal microbial composition (using 16S rRNA gene amplicon sequencing) and the levels of short-chain fatty acids (SCFAs) and ammonium ions (NH4+). Treatments T2 and T3 stimulated members of the Ruminococcaceae and Succinivibrionaceae families, which were positively correlated with an increase in butyric and acetic acids. Proteolytic bacteria were reduced by the two treatments, concurrently with a decrease in NH4+. Treatment T1 stimulated the production of butyric acid in the simulated transverse and descending colon, reduction of NH4+ as well as the growth of genera Lactobacillus, Megamonas, and members of Lachnospiracea. The results indicate that both B. longum BB-46 and pectin can modulate the obesity-related microbiota; however, when the pectin is combined with B. longum BB-46, the predominant effect of the pectin can be observed. This study showed that the citric pectin is able to stimulate butyrate-producing bacteria as well as genera related with anti-inflammatory effects. However, prospective clinical studies are necessary to evaluate the anti/pro-obesogenic and inflammatory effects of this pectin for future prevention of obesity.
Assuntos
Bactérias/isolamento & purificação , Bifidobacterium longum/fisiologia , Microbioma Gastrointestinal , Obesidade/microbiologia , Pectinas/metabolismo , Probióticos/administração & dosagem , Bactérias/classificação , Bactérias/genética , Bactérias/metabolismo , Butiratos/metabolismo , Ácidos Graxos Voláteis , Fezes/microbiologia , Fermentação , Humanos , Mucosa Intestinal/metabolismo , Intestinos/microbiologia , Obesidade/tratamento farmacológico , Obesidade/metabolismo , FilogeniaRESUMO
Abstract Probiotics have provided benefits to general health, but they are still insufficient to dental health. Objective: This study aimed to evaluate milk supplemented with probiotic bacteria and standard milk, measured by levels of Streptococcus mutans (S. mutans) and Lactobacillus spp., in 3-4-year-old children after 9 months of intervention. Material and Methods: The study was a triple-blind, placebo-controlled, randomized trial. The sample was composed of 363 preschoolers attending five child development centers in Cali, Colombia. They were randomized to two groups: children in the intervention group drank 200 mL of milk with Lactobacillus rhamnosus 5x106 and Bifidobacteruim longum 3x106, and children in the control group drank 200 mL of standard milk. Interventions occurred on weekdays and information was gathered through scheduled clinical examination. The primary result was the number of colony forming units (CFU) of S. mutans and Lactobacillus spp. in the saliva. Secondary results were dental caries, rated by the International Caries Detection and Assessment System (ICDAS), dental plaque, pH, and salivary buffer capacity. Results: The proportion of S. mutans was lower in the intervention group compared with the control group after 9 months; however, the differences did not reach statistical significance (p=0.173); on the other hand, statistically significant differences between groups were found in the CFU/mL of Lactobacillus spp. (p=0.002). There was not statistically significant difference in the prevalence of dental caries for both groups (p=0.767). Differences between groups were found in the salivary buffering capacity (p=0.000); neither salivary pH nor dental plaque were significantly different. Conclusions: Regular consumption of milk containing probiotics bacteria reduced CFU/mL of Lactobacillus spp. and increased salivary buffering capacity at 9 months of consumption.
Assuntos
Humanos , Animais , Masculino , Feminino , Pré-Escolar , Saliva/microbiologia , Streptococcus mutans/isolamento & purificação , Probióticos/administração & dosagem , Leite/química , Lactobacillus/isolamento & purificação , Fatores de Tempo , Contagem de Colônia Microbiana , Reprodutibilidade dos Testes , Resultado do Tratamento , Estatísticas não Paramétricas , Cárie Dentária/microbiologia , Cárie Dentária/prevenção & controle , Placa Dentária/microbiologia , Placa Dentária/prevenção & controle , Leite/microbiologiaRESUMO
Asthma is a chronic inflammatory disease that affects more females than males after puberty, and its symptoms and severity in women change during menstruation and menopause. Recently, evidence has demonstrated that interactions among the microbiota, female sex hormones, and immunity are associated with the development of autoimmune diseases. However, no studies have investigated if therapeutic gut microbiota modulation strategies could affect asthma exacerbation during menstruation and menopause. Here we aimed to examine the preventive effects of a probiotic, Bifidobacterium longum 51A, on airway inflammation exacerbation in allergic ovariectomized mice. We first evaluated the gut microbiota composition and diversity in mice 10 days after ovariectomy. Next, we examined whether re-exposure of ovariectomized allergic mice to antigen (ovalbumin) would lead to exacerbation of lung inflammation. Finally, we evaluated the preventive and treatment effect of B. longum 51A on lung inflammation and airway hyperresponsiveness. Our results showed that whereas ovariectomy caused no alterations in the gut microbiota composition and diversity in this animal model, 10 days after ovariectomy, preventive use administration of B. longum 51A, rather than its use after surgery was capable of attenuate the exacerbated lung inflammation and hyperresponsiveness in ovariectomized allergic mice. This prophylactic effect of B. longum 51A involves acetate production, which led to increased fecal acetate levels and, consequently, increased Treg cells in ovariectomized allergic mice.
RESUMO
Resumen: ANTECEDENTES: el estreñimiento, la distensión y el dolor abdominales son muy prevalentes en la población general y representan un reto terapéutico. Los probióticos han mostrado ser efectivos en el control de estos síntomas. OBJETIVO: investigar la utilidad clínica de la administración del simbiótico Bifidobacterium longum AW11 (5x109 UFC) y fructo-oligosacáridos de cadena corta (Fos cc. Actilight 2.5 g) en el alivio del estreñimiento y otros síntomas digestivos. PACIENTES Y MÉTODO: estudio abierto observacional en el que se incluyeron pacientes con síntomas digestivos de más de seis meses de evolución, sin enfermedad orgánica que explicara sus síntomas y que recibieron tratamiento con el simbiótico, un sobre diario durante ocho semanas. La intensidad y frecuencia de los síntomas se evaluaron mediante un cuestionario y las características de las evacuaciones mediante la escala de Bristol al inicio, a las cuatro y a las ocho semanas de tratamiento. RESULTADOS: se incluyeron 361 pacientes con síntomas digestivos. El promedio de la duración de los síntomas fue de 2.3±4.9 años, 96% tenía estreñimiento, 79% cumplió con criterios de síndrome de intestino irritable y 16% de estreñimiento funcional (Roma III). El número de evacuaciones semanales se incrementó de 3.8±3.3 iniciales a 5.9±3.0 en la semana 8 (p<0.00001). También mejoraron significativamente: el número de evacuaciones espontáneas completas, la consistencia de las heces (escala de Bristol) y la sensación global de bienestar y disminuyeron significativamente el esfuerzo al defecar, la distensión abdominal subjetiva, la frecuencia de dolor abdominal y la sensación de malestar abdominal. La proporción de pacientes totalmente satisfechos se incrementó de 6% al inicio a 78% en la semana 8. CONCLUSIONES: la administración diaria del simbiótico con B. longum y Fos cc. es eficaz para aliviar el estreñimiento y el dolor y la distensión abdominales.
Abstract: BACKGROUND: Constipation, abdominal pain and bloating are highly prevalent in general population and they constitute a therapeutic challenge. Probiotics are effective in the management of these symptoms. OBJECTIVE: To investigate in daily clinical practice if the administration of a supplement food containing Bifidobacterium longum AW11 (5x109 FCU) and short chain fructo-oligosaccharides (Fos cc. Actilight 2.5g) can relieve constipation and functional bowel symptoms. PATIENTS AND METHOD: An open and observational study was done including patients with digestive symptoms of more than six months of evolution, without organic disease explaining their symptoms and who received treatment with the synbiotic, daily during eight weeks. Intensity and frequency of symptoms were assessed by a questionnaire and the characteristics of evacuations by Bristol's scale at baseline and after four and eight weeks of treatment. RESULTS: There were included 361 patients with digestive symptoms lasting 2.3±4.9 years; 96% had constipation, 79% fulfilled Rome III criteria for irritable bowel syndrome an 16% for functional constipation. Treatment with the synbiotic increased frequency of bowel movements per week from 3.8±3.3 to 5.9±3.0 at week 8 (p<0.00001). There was a significant improvement also for: complete spontaneous bowel movements, stool consistency (Bristol scale), straining, bloating, frequency of abdominal pain, malaise, and global wellness. Percentage of patients with complete satisfaction increased from 6% in the initial visit to 78% at the week 8. CONCLUSIONS: Daily ingestion of a synbiotic (B. longum and Fos cc.) is effective to relieve constipation, abdominal pain and bloating.
RESUMO
AIM: To evaluate the treatment of pediatric functional chronic intestinal constipation (FCIC) with a probiotic goat yogurt. METHODS: A crossover double-blind formula-controlled trial was carried out on 59 students (age range: 5-15 years) of a public school in Belo Horizonte, MG, Brazil, presenting a FCIC diagnostic, according to Roma III criteria. The students were randomized in two groups to receive a goat yogurt supplemented with 10(9) colony forming unit/mL Bifidobacterium longum (B. longum) (probiotic) daily or only the yogurt for a period of 5 wk (formula). Afterwards, the groups were intercrossed for another 5 wk. Defecation frequency, stool consistency and abdominal and defecation pain were assessed. RESULTS: Both treatment groups demonstrated improvement in defecation frequency compared to baseline. However, the group treated with probiotic showed most significant improvement in the first phase of the study. An inversion was observed after crossing over, resulting in a reduction in stool frequency when this group was treated by formula. Probiotic and formula improved stool consistency in the first phase of treatment, but the improvement obtained with probiotic was significantly higher (P = 0.03). In the second phase of treatment, the group initially treated with probiotic showed worsening stool consistency when using formula. However, the difference was not significant. A significant improvement in abdominal pain and defecation pain was observed with both probiotic and formula in the first phase of treatment, but again the improvement was more significant for the group treated with B. longum during phase I (P < 0.05). When all data of the crossover study were analyzed, significant differences were observed between probiotic yogurt and yogurt only for defecation frequency (P = 0.012), defecation pain (P = 0.046) and abdominal pain (P = 0.015). CONCLUSION: An improvement in defecation frequency and abdominal pain was observed using both supplemented and non-supplemented yogurt, but an additional improvement with B. longum supplementation was obtained.
Assuntos
Bifidobacterium , Constipação Intestinal/dietoterapia , Probióticos/uso terapêutico , Iogurte/microbiologia , Dor Abdominal/dietoterapia , Dor Abdominal/etiologia , Adolescente , Criança , Pré-Escolar , Constipação Intestinal/complicações , Estudos Cross-Over , Defecação , Método Duplo-Cego , Feminino , Humanos , MasculinoRESUMO
Elaborou-se leite de búfala fermentado por Lactobacillus casei utilizando leite desnatado, adicionado de 12,00 de açúcar e fermentado por 24 horas. Após fermentação o produto foi suplementado com Bifidobacterium ongum e estocado durante 30 dias a 5 e 10ºC, sendo então avaliados os parâmetros de acidez, pH e viabilidade de L.casei e de B. longum. Realizou-se a análise de composição nutricional, cálculo do valor calórico e análise sensorial do produto saborizado. O leite fermentado suplementado com B. longum, apresentou acidez inicial de 0,69 e pH de 4,86. A viabilidade de L. casei inicial foi 11,00 log UFC/mL e de B. longum 10,46 log UFC/mL. Após 30 dias de estocagem refrigerada, a acidez e o pH estavam adequados e a viabilidade de L. casei e de B. longum ficou acima de 9,00 log UFC/mL. A análise da composição nutricional resultou nos valores (): proteína 3,63, carboidrato 21,86, gordura 0,10, resíduo mineral fixo 0,56, umidade 73,85 e matéria seca 26,15, com valor calórico de 103 Kcal/100g. Não houve diferença sifnificativa na preferência e na aceitação das amostras de diferentes sabores, sendo que o produto apresentou boa aceitação pela escala hedônica
It was elaborated fermented buffalo milk for L. casei utilizing skimmed milk added with 12,00% sugar andfermented by 24 hours. After fermentation, the product was supply with B. longum and storage during30 days at 5 and 10° C, being evaluated the acidity, pH and viability of L. casei and B. longum parameters.Were does the nutritional composition, calculate the caloric value and sensorial analysis of the flavoredproduct. The fermented milk presented initial acidity 0.69% and pH 4.86. The L. casei initial viability was11,00 log CFU/mL and B. longum 10,46 log CFU/mL. After storage of 30 days, the acidity and pH wereadequate and the L. casei and B. longum viability was above 9.00 log CFU/mL. The composition analysisresulted (%) protein 3.63, carbohydrate 21.86, fat 0.10, ashes 0.56, wet 73.85 and dry substance 26.15,with caloric value 103 Kcal/100 g. There wasn't significant difference to preference and acceptancebetween flavored samples, and have good acceptation by hedonic scale